journal article·2026-11Open access

Graphene oxide functionalized with polyamidoamine dendrimer as a drug delivery system for human breast cells

Beatriz Fumelli Monti Ribeiro, Julyane Batista Chaves, Siyu Fan, Harsh Jain, Laís Ribovski, Marcelo Medina de Souza, Renata Chaves Albuquerque, Daniele C. Ferreira, Paola Corio, Inge S. Zuhorn, Devaney Ribeiro do Carmo, Romana Schirhagl, Gláucia Maria Machado-Santelli

Abstract

The use of nanomaterials as drug carriers is an interesting area of research in the biomedical field due to their high efficiency and the potential for improved drug delivery systems. In this study, doxorubicin (DOX) is loaded onto the surface of graphene oxide (GOX) functionalized with Polyamidoamine Dendrimer amine-terminated generation 3, (PAMAM), covalently bound via amide formation between the peripheral amine groups of the dendrimers and the carboxyl groups present in GOX. We conducted multiple experiments to assess the efficacy of these treatments on human breast cells. The particles were characterized using Nanoparticle Tracking Analysis (NTA), Dynamic Light Scattering (DLS), Raman spectroscopy, Transmission Electron Microscopy (TEM), and Scanning Electron Microscopy (SEM). GOX + PAMAM (GOXP) showed an average diameter of 166 ± 118 nm, a positive surface charge (+7.5 mV), and a clustered organization with sheets of varying sizes. GOXP was located close to the cell nuclei. DOX was released from GOXP, with the release gradually increasing over time, leading to progressively reduced cell viability with extended exposure. Notably, the GOXP+DOX combination resulted in a significantly greater decrease in viability in tumor cell lines (MCF-7 and Hs578T) compared to free DOX. These results highlight the strong potential of GOXP+DOX as an effective and safe drug delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · Graphene and Nanomaterials Applications · Cancer Research and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (71)

Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Mechanisms of multidrug resistance in cancer chemotherapy10.3390/ijms21093233 ↗
3. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care10.1016/j.biopha.2021.112503 ↗
4. Overcoming Cancer Multi-drug Resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges10.1016/j.biopha.2023.114643 ↗
5. Smart targeting to improve cancer therapeutics10.2147/DDDT.S219489 ↗
6. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review10.1080/10717544.2022.2094498 ↗
7. Efficient gene silencing in intact plant cells using siRNA delivered by functional graphene oxide nanoparticles
8. Nano-based drug delivery system for therapeutics: a comprehensive review10.1088/2057-1976/acedb2 ↗
9. Liposomal nano-based drug delivery systems for breast cancer therapy: recent advances and progresses10.2174/0118715206293653240322041047 ↗
10. Recent advances in nano-based drug delivery systems for treatment of liver cancer10.1016/j.xphs.2024.08.012 ↗
11. Functionalized graphene oxide as a vehicle for targeted drug delivery and bioimaging applications10.1039/D0TB01149E ↗
12. Functionalized graphene platforms for anticancer drug delivery10.2147/IJN.S249712 ↗
13. Recent biomedical advancements in graphene oxide- and reduced graphene oxide-based nanocomposite nanocarriers10.1186/s40824-022-00313-2 ↗
14. New insights into the activities and toxicities of the old anticancer drug doxorubicin10.1111/febs.15583 ↗
15. Hybrid graphene oxide/DAB-Am-16 dendrimer: preparation, characterization chemical reactivity and their electrocatalytic detection of l-Dopamine10.1016/j.solidstatesciences.2017.07.005 ↗
16. Incorporation of Carvedilol into PAMAM-functionalized MWNTs as a sustained drug delivery system for enhanced dissolution and drug-loading capacity
17. A novel digitonin/graphene oxide/iron oxide nanocomposite: synthesis, physiochemical characterization and antioxidant activity10.1186/s11671-024-03960-7 ↗
18. Graphene oxide nanosheets for bone tissue regeneration10.3390/molecules29143263 ↗
19. Three-dimensional self-assembly of graphene oxide and DNA into multifunctional hydrogels10.1021/nn1027104 ↗
20. One-step synthesis of Graphene Oxide-Polyamidoamine dendrimer nanocomposite hydrogels by self-assembly10.1021/acs.iecr.6b00947 ↗
21. Evolution of the Raman spectrum with the chemical composition of graphene oxide10.1021/acs.jpcc.7b06236 ↗
22. Dependence of Graphene Oxide (GO) toxicity on oxidation level, elemental composition, and size10.3390/ijms221910578 ↗
23. A comparative study of particle size distribution of graphene nanosheets synthesized by an ultrasound-assisted method10.3390/nano9020152 ↗
24. Differential toxicity of graphene family nanomaterials concerning morphology10.1007/978-981-16-4923-3_2 ↗
25. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates10.1007/s11095-010-0073-2 ↗
26. Physical characterization and profiling of airway epithelial derived exosomes using light scattering10.1016/j.ymeth.2015.03.013 ↗
27. Nanoparticle tracking analysis: an effective tool to characterize extracellular vesicles10.3390/molecules29194672 ↗
28. Impact of physico-chemical properties on the toxicological potential of reduced graphene oxide in human bronchial epithelial cells10.1080/17435390.2023.2265465 ↗
29. DLS and zeta potential - what they are and what they are not?10.1016/j.jconrel.2016.06.017 ↗
30. Effects of the surface charge of graphene oxide derivatives on ocular compatibility10.3390/nano12050735 ↗
31. Combination of surface charge and size controls the cellular uptake of functionalized graphene sheets10.1002/adfm.201701837 ↗
32. Synthesis of polymer-functionalized nanoscale graphene oxide with different surface charge and its cellular uptake, biosafety and immune responses in Raw264.7 macrophages10.1016/j.msec.2018.04.096 ↗
33. Graphene oxide hosting a pH-sensitive prodrug: an in silico investigation of graphene oxide-based nanovehicle toward cancer therapy10.1021/acsabm.3c00276 ↗
34. A novel pH-sensitive nanocomposite based on graphene oxide for improving doxorubicin release10.2174/1567201820666230413094206 ↗
35. Current principles, challenges, and new metrics in pH-responsive drug delivery systems for systemic cancer therapy10.3390/pharmaceutics15051566 ↗
36. A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment10.1038/s41598-022-05793-9 ↗
37. PEGylated DOX-coated nano graphene oxide as pH-responsive multifunctional nanocarrier for targeted drug delivery10.1080/1061186X.2021.1887200 ↗
38. Synthesis, characterization, and evaluation of pH-sensitive doxorubicin-loaded functionalized graphene oxide in osteosarcoma cells
39. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide10.1021/jp806751k ↗
40. Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug
41. Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide10.1016/j.msec.2015.10.065 ↗
42. Synergistic performance of triggered drug release and photothermal therapy of MCF7 cells based on laser activated PEGylated GO + DOX10.1364/BOE.389261 ↗
43. Synthesis and characterization of a novel multi-functionalized reduced graphene oxide as a pH-sensitive drug delivery material and a photothermal candidate10.1016/j.apsusc.2022.152568 ↗
44. Doxorubicin drug release behavior from amino-silanated graphene oxide nanocarrier10.1016/j.diamond.2022.109569 ↗
45. Biocompatible functionalized graphene nanosheet for delivery of doxorubicin to breast cancer cells10.1016/j.jddst.2022.103234 ↗
46. The characters of graphene oxide nanoparticles and doxorubicin against HCT-116 colorectal cancer cells in vitro10.1007/s12029-021-00625-x ↗
47. Polymeric graphene oxide nanoparticles loaded with doxorubicin for combined photothermal and chemotherapy in triple negative breast cancer10.1016/j.bioadv.2023.213550 ↗
48. Recent advances in targeted strategies for triple-negative breast cancer10.1186/s13045-023-01497-3 ↗
49. Imaging challenges in diagnosing triple-negative breast cancer10.1148/rg.230027 ↗
50. Reactive Oxygen Species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
51. A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy10.1039/D3NR01735D ↗
52. Toxicity of carbon nanomaterials and their potential application as drug delivery systems: in vitro studies in Caco-2 and MCF-7 cell lines10.3390/nano10081617 ↗
53. Surface oxidation of graphene oxide determines membrane damage, lipid peroxidation, and cytotoxicity in macrophages in a pulmonary toxicity model10.1021/acsnano.7b07737 ↗
54. Oxygen content-related DNA damage of graphene oxide on human retinal pigment epithelium cells10.1007/s10856-021-06491-0 ↗
55. Interaction of graphene oxide nanoparticles with human mesenchymal stem cells visualized in the cell-IQ system10.3390/molecules28104148 ↗
56. Toxicity of graphene oxide on intestinal bacteria and Caco-2 cells10.4315/0362-028X.JFP-14-463 ↗
57. Graphene oxide enhanced cisplatin cytotoxic effect in glioblastoma and cervical cancer10.3390/molecules28176253 ↗
58. Graphene oxide/chitosan injectable composite hydrogel for controlled release of doxorubicin: an approach for enhanced intratumoral delivery10.3390/nano12234261 ↗
59. Quantifying the level of nanoparticle uptake in mammalian cells using flow cytometry10.1039/D0NR01627F ↗
60. A targeted and pH-responsive nano-graphene oxide nanoparticle loaded with doxorubicin for synergetic chemo-photothermal therapy of oral squamous cell carcinoma10.2147/IJN.S402249 ↗
61. Applications of graphene oxide in case of nanomedicines and nanocarriers for biomolecules: review study10.1080/03602532.2018.1522328 ↗
62. Derivatives of graphene oxide as potential drug carriers10.1166/jnn.2019.15855 ↗
63. Controllability of graphene oxide doxorubicin loading capacity based on density functional theory10.3390/nano12030479 ↗
64. Graphene oxide and its nanocomposites with EDTA or chitosan induce apoptosis in MCF-7 human breast cancer10.1039/D1RA04345E ↗
65. Cerium oxide/graphene oxide hybrid: synthesis, characterization, and evaluation of anticancer activity in a breast cancer cell line (MCF-7)10.3390/biomedicines11020531 ↗
66. Well-defined graphene oxide as a potential component in lung cancer therapy10.2174/1568009619666191021113807 ↗
67. Graphene oxide nanoribbons induce autophagic vacuoles in neuroblastoma cell lines10.3390/ijms17121995 ↗
68. Graphene oxide induced perturbation to plasma membrane and cytoskeletal meshwork sensitize cancer cells to chemotherapeutic agents10.1021/acsnano.6b07311 ↗
69. Autophagy modulation in therapeutic strategy of breast cancer drug resistance10.7150/jca.97775 ↗
70. The reduced graphene oxide (rGO) induces apoptosis, autophagy and cell cycle arrest in breast cancer cells10.3390/ijms23169285 ↗
71. Graphene oxide nanocolloids induce autophagy-lysosome dysfunction in mouse embryonic stem cells10.1166/jbn.2019.2684 ↗